Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC

NCT05956639 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Interventions

DRUG: 6-month course of antiandrogen drugs
DRUG: Long-term course of antiandrogen drugs

Sponsor

The First Affiliated Hospital with Nanjing Medical University